Publisher
Springer Science and Business Media LLC
Reference190 articles.
1. Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4:247–61.
2. Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18:583–92.
3. Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685–96.
4. Kent D, Rickwood S, and Di Biase S. Disruption and maturity: the next phase of biologics. 2017; https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next_phase_of_biologics.pdf?_=1518214264988. Accessed 17 Dec 2019.
5. van den Hoven A. Biosimilar medicines clinical use: an experience-based EU perspective. 2017; https://www.medicinesforeurope.com/docs/20170713%20-%20Biosimilar%20Medicines%20Group,%20EU%20experience-AVH-US%20FDA%20Adcom.pdf. Accessed 17 Dec 2019.
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献